Comparing apixaban and warfarin for peritoneal dialysis patients with atrial fibrillation
Part of Heart & circulation clinical trials.
This trial compares two blood thinners, apixaban and warfarin, in people on peritoneal dialysis who have atrial fibrillation (an irregular heartbeat). The goal is to see which one works better and is safer for preventing strokes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have been on peritoneal dialysis for at least 3 months.
- You have atrial fibrillation that is not caused by a heart valve problem, and you either already take blood thinners or need to start them.
- Your doctor has determined you have a high risk of stroke (CHA2DS2-VASc score of 2 or more).
- You have not had a stroke or mini-stroke in the last 3 months.
- You are not on hemodialysis, and you are not expecting a kidney transplant in the next 3 months.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you use effective contraception if you are a woman of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how apixaban (a blood thinner) moves through the body in people who are on peritoneal dialysis and have non-valvular atrial fibrillation. It may help confirm the safest and most effective dosing for patients who have little or no remaining kidney function.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This study compares two ways to manage atrial fibrillation (an irregular heartbeat) in people on dialysis. One approach uses a blood thinner called apixaban, and the other does not use blood thinners. The goal is to see which approach better prevents strokes and bleeding.
This study compares two common blood thinners, apixaban and rivaroxaban, in veterans with atrial fibrillation or flutter to see which one is safer and works better. If you are already taking one of these medicines, you may be able to join.
This trial compares the bleeding risk of two commonly used blood thinners—rivaroxaban and apixaban—in people with atrial fibrillation (AF). If you’re starting an anticoagulant for a new AF diagnosis, this may help doctors choose the safer option for you and others.
This trial is testing two blood thinners (edoxaban and apixaban) to see how they compare in preventing new brain spots on MRI after a stroke in people with atrial fibrillation. It may help you and your doctor choose the safer option.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.